{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 29,
  "pageCount": 415,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Uses patient testimonials as primary evidence to challenge the safety profile of the drug.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/29",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-29",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The critical part of the narrative: diuretics were insufficient to manage the crisis, indicating Vykat-induced edema is a feature not a bug – and by inference, so is the risk of pulmonary involvement and heart failure.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acac-60c3e6b7a4a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.86,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "image",
      "text": "Screenshots of Facebook discussion group posts detailing the patient's experience with Vykat and Lasix.",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "451a9287-3feb-4156-abe6-d1edd1f1f87e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The family paused Vykat for two days for an emergency course of Lasix (furosemide), typically IV-administered in an urgent care setting for rapid fluid removal in case of pulmonary edema or congestive heart failure. It is an extremely potent diuretic that requires close monitoring for electrolyte and kidney-related complications. After then re-starting Vykat, the child re-gained 5 lbs of fluid – “I was a bit shocked at a 5lb gain!” Ten days later, the family gave up and stopped the drug: “even on a lower dose and Lasix she still seemed to have some fluid retention...[she] has been pretty vocal about wanting to stop the Vykat because the swelling hurt her legs.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a23f6c9-cf52-4c07-91f6-ff005b9f52d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "I was a bit shocked at a 5lb gain! — Patient/Caregiver in Vykat discussion group. \"even on a lower dose and Lasix she still seemed to have some fluid retention...[she] has been pretty vocal about wanting to stop the Vykat because the swelling hurt her legs.\" — Patient/Caregiver in Vykat discussion group.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acac-6506c3a75010",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: Facebook groups – “Vykat discussion group”",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c41c3c7-97d8-40ce-9b73-a296263eae2b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "c5ec7339-6167-452b-b309-f8869e57e658",
      "evidence": "Frames the drug (Vykat) as the antagonist causing harm.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}